A city-based wholesaler of pharmaceutical products had alleged that the company violated competition norms by refusing to supply medicines to it and also abused the dominant position.
While rejecting the complaint, CCI said Abbott Healthcare has "sufficient commercial reasons for not supplying the medicines" to the informant and its refusal cannot be held to be in violation of Section 3.
Section 3 of the Competition Act pertains to anti- competitive agreements.
"There is no specific information available in the public domain to suggest that the Opposite Party (Abbott Healthcare) is dominant in any particular market," Competition Commission of India (CCI) said in an order on Wednesday.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
